This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is ACADIA (ACAD) Likely to Beat Earnings Estimates in Q3?
by Zacks Equity Research
ACADIA Pharmaceuticals' (ACAD) antipsychotic drug, Nuplazid, is expected to record strong sales in the third quarter despite increased prices backed by higher demand.
Will Endocyte (ECYT) Disappoint This Earnings Season?
by Zacks Equity Research
Endocyte (ECYT) plans to focus on its most promising programs like CAR T-cell small-molecule drug conjugates (SMDC) adaptor platform and its pipeline candidate EC2629 in Q3.
Jazz Pharmaceuticals (JAZZ) Q3 Earnings: A Beat in Store?
by Zacks Equity Research
Jazz Pharmaceuticals' (JAZZ) lead drug, Xyrem, is likely to deliver a strong performance in Q3, thanks to label expansion efforts. Also, other products look promising to lead to an earnings beat.
Is a Beat in the Cards for Mylan (MYL) This Earnings Season?
by Zacks Equity Research
Mylan N.V. (MYL) is likely to beat results when it reports third-quarter results next week driven by newly launched generics.
What's in the Cards for Prothena (PRTA) in Q3 Earnings?
by Zacks Equity Research
Investors focus should remain on pipeline updates when Prothena Corporation (PRTA) reports third-quarter results as it has no approved product in its portfolio.
What's in the Cards for Arena (ARNA) This Earnings Season?
by Zacks Equity Research
Although Belviq, the only approved product in Arena's (ARNA) portfolio, has an unimpressive show so far, the company's efforts to improve the drug's performance might drive the stock in Q3.
Ball Corporation (BLL) to Post Q3 Earnings: What to Expect?
by Zacks Equity Research
Ball Corporation's (BLL) Q3 results are likely to benefit from improvement in food and aerosol business. However, additional depreciation and non-steel related amortization expense are headwinds.
Is a Beat in Store for Zoetis (ZTS) This Earnings Season?
by Zacks Equity Research
Zoetis' (ZTS) top line is expected to be driven by newly launched Apoquel, Simparica and Cytopoint. The approvals of Clavamox and Nexvet are expected to boost sales further.
Valeant Reports Positive Results on Psoriasis Drug Siliq
by Zacks Equity Research
Valeant Pharmaceuticals International, Inc. (VRX) announced encouraging results from the long-term phase III extension study, AMAGINE-2 on psoriasis drug Siliq.
Lilly's Verzenio Gets Priority Review in First-Line Setting
by Zacks Equity Research
Eli Lilly and Company (LLY) announced that the FDA has granted priority review to its new drug application for Verzenio (abemaciclib) for the first-line treatment of advanced breast cancer.
Here's Why Intercept (ICPT) Stock Lost 37% So Far in 2017
by Zacks Equity Research
Shares of Intercept Pharmaceuticals (ICPT) have plunged 37% in the year so far due to safety issues regarding approved drug Ocaliva.
Allergan's Uterine Fibroids Candidate's NDA Accepted by FDA
by Zacks Equity Research
Allergan plc (AGN) announced that the FDA has accepted the new drug application (NDA) for ulipristal acetate, for the treatment of abnormal uterine bleeding in women with uterine fibroids.
Mallinckrodt to Begin Sarcoidosis Study on Acthar Gel
by Zacks Equity Research
Mallinckrodt plc (MNK) announced that it will initiate a new phase IV study on H.P. Acthar Gel as a therapy option in patients with symptomatic sarcoidosis.
Why Should You Invest in Novo Nordisk (NVO) Stock Right Now
by Zacks Equity Research
Novo Nordisk (NVO) has a strong presence in the Diabetes care market and the current quarter has seen some events happening for the company that bode well for its growth.
AstraZeneca's Tagrisso Gets Breakthrough Therapy Designation
by Zacks Equity Research
AstraZeneca (AZN) obtained Breakthrough Therapy Designation (BTD) for Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer.
Emergent BioSolutions Acquires Sanofi's Smallpox Vaccine Unit
by Zacks Equity Research
Emergent BioSolutions (EBS) announced that it has acquired FDA-licensed smallpox vaccine's business of Sanofi (SNY) ??? ACAM2000.
Roche (RHHBY) Receives FDA Approval For Cobas Zika Test
by Zacks Equity Research
The approval of cobas Zika will expands Roche's industry-leading donor screening portfolio for blood-borne diseases.
ACADIA's Antipsychotic Drug Gets Breakthrough Therapy Status
by Zacks Equity Research
ACADIA Pharmaceuticals' (ACAD) Nuplazid granted Breakthrough Therapy Designation for dementia-related psychosis. A phase III study for the same was also initiated.
Ligand (LGND) Signs Deal to Acquire Crystal Bioscience
by Zacks Equity Research
Ligand (LGND) inked a deal to acquire Crystal Bioscience, a leader in chicken-derived fully-human antibody generation, for $25 million in cash.
Celsion's Immunotherapy Candidate Impresses, Stock Surges
by Zacks Equity Research
Celsion's (CLSN) pipeline candidate, GEN1, controls ovarian cancer in all patients in the phase Ib study and achieves a historical improvement in progression free survival.
Emergent Completes Acquisition of Anthrax Drug Raxibacumab
by Zacks Equity Research
Emergent BioSolutions Inc. (EBS) completes the acquisition of anthrax monoclonal antibody, raxibacumab, from GlaxoSmithkline.
Allergan Authorizes New $2B Share Buyback Plan, Stock Up
by Zacks Equity Research
Allergan plc (AZN) sanctions a new stock repurchase program. The company also reiterates its commitment toward annual hike of quarterly cash dividend.
Glaxo-Innoviva's Triple Combo Inhaler Positive in Phase III
by Zacks Equity Research
GlaxoSmithKline plc (GSK) along with partner Innoviva reports positive results from a phase III study, evaluating a single inhaler triple therapy in patients with COPD.
Supernus Drops SPN-810's Lower Dose Test in Phase III Trials
by Zacks Equity Research
Supernus (SUPN) decides to stop evaluating the lower dose option of SPN-810 for treatment of impulsive aggression. However, the company will carry on with the study of higher dose arm or placebo.
Glaxo/Innoviva's Triple Combo Therapy Gets FDA Nod for COPD
by Zacks Equity Research
The FDA approves GlaxoSmithKline (GSK) and Innoviva's triple combination therapy, FF/UMEC/VI, for COPD. The drug will be accessed as Trelegy Ellipta in the U.S. market.